Treg Cell-based Therapies refer to therapeutic approaches
that utilize regulatory T cells (Tregs) to modulate the immune
system. Innovations in cell expansion and engineering techniques
have greatly enhanced the ability to isolate, expand, and deliver
functional Tregs. Ex vivo expansion technologies and genetic
engineering (such as CAR-Tregs) have opened up new possibilities
for enhancing the stability, specificity, and effectiveness of Treg
therapies.
LAS
VEGAS, Oct. 28, 2024 /PRNewswire/ --
DelveInsight's 'Treg Cell-based Therapies Pipeline
Insight 2024' report provides comprehensive global
coverage of available, marketed, and pipeline Treg cell-based
therapies in various stages of clinical development, major
pharmaceutical companies are working to advance the pipeline space
and future growth potential of the Treg cell-based therapies
pipeline domain.
Key Takeaways from the Treg Cell-based Therapies Pipeline
Report
- DelveInsight's Treg cell-based therapies pipeline report
depicts a robust space with 50+ active players working to
develop 55+ pipeline therapies for various
indications.
- Key Treg cell-based therapies companies such as Orca Bio,
Nektar Therapeutics, Quell Therapeutics, Cugene, Sangamo
Therapeutics, Abata Therapeutics, HCW Biologics, GentiBio, Tr1X,
PolTREG, Cellenkos, VT BIO, Miltenyi Biotec GmbH, KSQ Therapeutics,
TeraImmune, Tract Therapeutics, and others are evaluating new
Treg cell-based therapies to improve the treatment
landscape.
- Promising Treg cell-based therapies in the pipeline in various
stages of development include Orca-T, NKTR-358, QEL-001,
CUG-252, TX200, ABA-101, HCW9302, GNTI-122, TRX-103, PTG-020,
CK-0804, VT-301, TR-004, KSQ 001, TI-620, TRK 001, and
others.
- In October 2024, Quell
Therapeutics hired eXmoor Pharma to make supplies of its pipeline
of novel immunosuppressive cell therapies—called CAR-Tregs—at its
new cell and gene therapy facility. Quell recently teamed with
fellow U.K.-based eXmoor in a strategic partnership that will see
the contractor make its candidate autoimmune disease cell therapies
for early-phase clinical studies.
- In September 2024, Abata
Therapeutics announced that ABA-101, an autologous regulatory
T-cell (Treg) therapy for the treatment of patients with
progressive multiple sclerosis (MS), has received fast-track
designation from the US FDA.
- In September 2024, PolTREG S.A.
announced that China's National
Intellectual Property Administration, PRC (CNIPA) had issued a
notification to grant a patent for the intrathecal administration
of the company's cellular therapies in patients with multiple
sclerosis (MS). The intrathecal administration is an established
method used to deliver therapy across the blood-brain barrier via
injection into the subarachnoid space.
- In June 2024, Orca Bio announced
that it had completed enrollment in the pivotal Precision-T Phase
III clinical study. The primary endpoint of the Precision-T study
is the rate of survival free from moderate-to-severe chronic graft
versus host disease (GvHD).
- In March 2024, PolTREG announced
that the company is planning to launch Phase II trials testing its
Tregs therapy — the T-cell-based treatment PTG-007 in people with
multiple sclerosis (MS).
- In February 2024, Cellenkos
announced encouraging safety data from its innovative CK0803
neurotrophic T regulatory (Treg) cell therapy, being developed to
help treat individuals with Amyotrophic Lateral Sclerosis (ALS).
The company was given the green light to move ahead following a
review of safety data by the Data Safety Monitoring Board
(DSMB).
- In August 2023, BlueRock
Therapeutics LP, a wholly owned, independently operated subsidiary
of Bayer AG, and bit.bio, the company coding human cells for novel
cures announced a collaboration and option agreement for the
discovery and manufacture of iPSC-derived regulatory T cells
(Tregs) for use in creating therapeutics.
Request a sample and discover the recent advances in Treg
cell-based therapies @ Treg Cell-based Therapies Pipeline
Outlook
The Treg cell-based therapies pipeline report provides detailed
profiles of pipeline assets, a comparative analysis of clinical and
non-clinical stage Treg cell-based therapies, inactive and dormant
assets, a comprehensive assessment of driving and restraining
factors, and an assessment of opportunities and risks in the Treg
cell-based therapies pipeline landscape.
Treg Cell-based Therapies Overview
Treg cell-based therapies represent a promising frontier in
immunotherapy, focusing on harnessing regulatory T cells (Tregs) to
modulate the immune response in various clinical settings. Tregs
play a crucial role in maintaining immune homeostasis and
preventing autoimmune reactions by suppressing excessive immune
responses. In the context of autoimmune diseases, these therapies
aim to restore balance by expanding or enhancing Tregs to dampen
inappropriate immune activity. For instance, in diseases like type
1 diabetes or multiple sclerosis, Treg cell-based treatments seek
to prevent or slow disease progression by reestablishing immune
tolerance.
Beyond autoimmune disorders, Treg cell-based therapies are also
being explored in cancer treatment. Tumors often exploit Tregs to
evade immune detection, and by manipulating these cells, it's
possible to enhance the anti-tumor immune response. Strategies
include expanding Tregs ex vivo and reinfusing them to boost their
numbers or modifying them to more effectively target
tumor-associated antigens. These approaches hold the potential to
improve the efficacy of existing immunotherapies and offer new
avenues for treating cancers that are currently resistant to
conventional treatments.
Find out more about Treg cell-based therapies @ Treg
Cell-based Therapies in Development
A snapshot of the Treg Cell-based Therapies Pipeline Drugs
mentioned in the report:
Drugs
|
Company
|
Phase
|
Indication
|
MoA
|
RoA
|
Orca-T
|
Orca Bio
|
Phase III
|
Acute myeloid leukemia;
Myelodysplastic syndromes; Precursor cell lymphoblastic
leukemia-lymphoma
|
Immunologic
cytotoxicity; T lymphocyte replacements
|
Parenteral
|
NKTR-358
|
Nektar
Therapeutics
|
Phase II
|
Alopecia areata; Atopic
dermatitis; Systemic lupus erythematosus
|
Interleukin 2
replacements
|
Subcutaneous
|
CLBS03
|
Caladrius
Biosciences
|
Phase II
|
Type 1 diabetes
mellitus
|
T lymphocyte
replacements
|
Intravenous
|
QEL-001
|
Quell
Therapeutics
|
Phase I/II
|
Liver transplant
rejection
|
Immunologic
cytotoxicity; Regulatory T-lymphocyte replacements
|
Intravenous
|
CUG-252
|
Cugene
|
Phase I
|
Atopic dermatitis;
Inflammatory bowel diseases; Rheumatoid arthritis; Systemic lupus
erythematosus
|
Interleukin 2
replacements
|
Subcutaneous
|
VT301
|
VT BIO
|
Phase I
|
Alzheimer's
disease
|
Cell
replacements
|
Parenteral
|
Learn more about the emerging Treg cell-based therapies @
Treg Cell-based Therapies Clinical Trials
Treg Cell-based Therapies Therapeutics Assessment
The Treg cell-based therapies pipeline report proffers
an integral view of the emerging Treg cell-based therapies
segmented by stage, product type, molecule type, mechanism of
action, and route of administration.
Scope of the Treg Cell-based Therapies Pipeline
Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono,
Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery,
Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of
Administration: Intravenous, Subcutaneous, Oral,
Intramuscular
- Therapeutics Assessment By Molecule
Type: Monoclonal antibody, Small molecule, Peptide
- Therapeutics Assessment By Mechanism of
Action: Immunologic cytotoxicity, T lymphocyte replacements,
Interleukin 2 replacements, Cell replacements
- Key Treg Cell-based Therapies Companies: Orca
Bio, Nektar Therapeutics, Quell Therapeutics, Cugene, Sangamo
Therapeutics, Abata Therapeutics, HCW Biologics, GentiBio, Tr1X,
PolTREG, Cellenkos, VT BIO, Miltenyi Biotec GmbH, KSQ Therapeutics,
TeraImmune, Tract Therapeutics, and others.
- Key Treg Cell-based Therapies in Pipeline: Orca-T,
NKTR-358, QEL-001, CUG-252, TX200, ABA-101, HCW9302, GNTI-122,
TRX-103, PTG-020, CK-0804, VT-301, TR-004, KSQ 001, TI-620, TRK
001, and others.
Dive deep into rich insights for Treg cell-based therapies
assessment, visit @ Treg Cell-based Therapies Therapeutics
Assessment
Table of Contents
1.
|
Treg Cell-based
Therapies Pipeline Report Introduction
|
2.
|
Treg Cell-based
Therapies Pipeline Report Executive Summary
|
3.
|
Treg Cell-based
Therapies Pipeline: Overview
|
4.
|
Analytical Perspective
In-depth Commercial Assessment
|
5.
|
Treg Cell-based
Therapies Pipeline Therapeutics
|
6.
|
Treg Cell-based
Therapies Pipeline: Late Stage Products
(Pre-registration)
|
7.
|
Treg Cell-based
Therapies Pipeline: Late Stage Products (Phase III)
|
8.
|
Treg Cell-based
Therapies Pipeline: Mid Stage Products (Phase II)
|
9
|
Treg Cell-based
Therapies Pipeline: Early Stage Products (Phase I)
|
10.
|
Treg Cell-based
Therapies Pipeline Therapeutics Assessment
|
11.
|
Inactive Products in
the Treg Cell-based Therapies Pipeline
|
12.
|
Company-University
Collaborations (Licensing/Partnering) Analysis
|
13.
|
Key
Companies
|
14.
|
Key Products in the
Treg Cell-based Therapies Pipeline
|
15.
|
Unmet Needs
|
16.
|
Market Drivers and
Barriers
|
17.
|
Future Perspectives and
Conclusion
|
18.
|
Analyst
Views
|
19.
|
Appendix
|
For further information on the Treg cell-based
therapies pipeline therapeutics, reach out @ Treg
Cell-based Therapies Pipeline Landscape
Related Reports
Type 1 Diabetes Market
Type 1 Diabetes Market Insights, Epidemiology, and
Market Forecast – 2032 report deliver an in-depth understanding
of the disease, historical and forecasted epidemiology, as well as
the market trends, market drivers, market barriers, and key type 1
diabetes companies, including Histogen, Novo
Nordisk, Prevention Bio, among others.
Diabetes Market
Diabetes Market Insights, Epidemiology, and Market
Forecast – 2032 report deliver an in-depth understanding of the
disease, historical and forecasted epidemiology, as well as the
market trends, market drivers, market barriers, and key
diabetes companies, including TikoMed, Avotres, REMD
Biotherapeutics, Novo Nordisk, among others.
Alzheimer's Disease Market
Alzheimer's Disease Market Insights, Epidemiology, and
Market Forecast – 2034 report deliver an in-depth understanding
of the disease, historical and forecasted epidemiology, as well as
the market trends, market drivers, market barriers, and key
Alzheimer's disease companies, including BioVie, AB
Science, Cassava Sciences, TauRx Therapeutics, Novo Nordisk, Eli
Lilly, Athira Pharma, Alzheon, Eisai, among others.
Alzheimer's Disease Pipeline
Alzheimer's Disease Pipeline Insight – 2024 report
provides comprehensive insights about the pipeline landscape,
pipeline drug profiles, including clinical and non-clinical stage
products, and the key Alzheimer's Disease companies,
including Biogen, AZTherapies, Cerecin, Neurotrope,
Synaptogenix, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB
Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time
Therapeutics, Denali Therapeutics Inc., Alector Inc., Lexeo
Therapeutics, TrueBinding, Inc., Vaccinex Inc., Annovis Bio Inc.,
Eisai Inc., Hoffmann-La Roche, Ionis Pharmaceuticals, Inc.,
Otsuka Pharmaceutical Co., Ltd., Cognition Therapeutics,
Merck Sharp & Dohme LLC, ImmunoBrain Checkpoint, AbbVie, AriBio
Co., Ltd., Oryzon Genomics S.A., Eli Lilly and Company,
Neurokine Therapeutics, Excelsior, Seelos Therapeutics, Inc.,
Janssen Research & Development, LLC, Shanghai Hengrui
Pharmaceutical Co., Ltd., reMYND, Alzinova AB, VTBIO Co. LTD,
BioVie Inc., Prothena Corporation plc, Coya Therapeutics, Inc.,
among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market
Research firm focused exclusively on life sciences. It supports
pharma companies by providing comprehensive end-to-end solutions to
improve their performance. Get hassle-free access to all the
healthcare and pharma market research reports through our
subscription-based platform PharmDelve.
Contact Us
Shruti
Thakur
info@delveinsight.com
+14699457679
Logo:
https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/treg-cell-based-therapies-clinical-trial-pipeline-appears-robust-with-51-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-302288345.html